Mostrando 4,581 - 4,600 Resultados de 5,896 Para Buscar 'Asentiú~', tiempo de consulta: 1.76s Limitar resultados
  1. 4581
  2. 4582
  3. 4583
  4. 4584
  5. 4585
  6. 4586
  7. 4587
  8. 4588
  9. 4589
  10. 4590
  11. 4591
  12. 4592
  13. 4593
    “…AIMS: To assess the efficacy, insulin dose, safety and immunogenicity when people with type 1 diabetes mellitus switched between MYL‐1501D and reference insulin glargine (Lantus®; Sanofi‐Aventis US LLC, Bridgewater, New Jersey). MATERIALS AND METHODS: Eligible participants from INSTRIDE 1 who completed 52 weeks of reference insulin glargine treatment were randomized 1:1 to the reference sequence (n = 63; reference insulin glargine for 36 weeks) or to the treatment‐switching sequence (n = 64; MYL‐1501D [weeks 0–12], reference insulin glargine [weeks 12–24] and MYL‐1501D [weeks 24–36]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 4594
  15. 4595
  16. 4596
  17. 4597
  18. 4598
  19. 4599
  20. 4600
Herramientas de búsqueda: RSS